Drug intelligence / Profile preview

milrovekide

Development stage: Preclinical
Lead developer: Kalohexis
Modality: Peptides

Overview

Milrovekide (TCMC897) is a therapeutic peptide developed by Kalohexis that acts as a dual antagonist of the melanocortin 3 receptor (MC3R) and melanocortin 4 receptor (MC4R). It is specifically designed for the treatment of cancer cachexia in patients with advanced cancers. By antagonizing these central receptors, milrovekide aims to block the signaling pathways that drive appetite suppression and muscle wasting, thereby promoting weight maintenance or gain in cachectic patients. The drug is currently in the IND-enabling stage of development.

Targets

MC4R (Melanocortin 4 receptor)MC3R (Melanocortin Receptor Type 3)

Beyond the preview

Go deeper on milrovekide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on milrovekide.

Explore the full profile